ProCE Banner Activity

ASCENT: Patient Subgroup Analyses of Sacituzumab Govitecan vs Single-Agent CT in Metastatic TNBC After ≥2 Prior CT Regimens

Slideset Download
Conference Coverage
In subgroup analyses of the phase III ASCENT trial, sacituzumab govitecan maintained benefit and a consistent safety profile vs single-agent chemotherapy among patients aged ≥65 years, among those in the second-line setting with disease TNBC recurrence ≤12 months after (neo)adjuvant therapy, and when compared with individual chemotherapy agents.

Released: June 08, 2021

Expiration: June 07, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Amgen, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.


Gilead Sciences, Inc.


Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme